Pasithea Therapeutics Corp (KTTA) Stock Price, Quote & News

Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, inclu...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 977 3380

Website: www.pasithea.com

Address:

1111 Lincoln Road, Suite 500, Miami Beach, United States

Napoliblue Sep. 13 at 4:22 AM

$KTTA this stock is dead when is the reverse split ? In the September 2025 annual meeting, shareholders approved giving the Board the authority to carry out another reverse stock split at a ratio somewhere between 1-for-2 and 1-for-20, to be executed any time before September 3, 2026, without further shareholder approval.

0 · Reply

Amcollins711 Sep. 11 at 3:57 PM

$MRKR $KTTA my next two

0 · Reply

dustbunnies Sep. 9 at 8:15 AM

$KTTA have the phase 1 results been announced?

0 · Reply

TraderJay85 Sep. 8 at 4:08 PM

$NXTT $AEI $KTTA $GYRO Got in early on all these and banked. small losses or big gains. thats it! thats how you make a living off the stock market. get in early, have a plan, and profit. NO discords, NO email lists, or 3 other social media platforms. Just hit the follow and we all make money together! $SWIN is my next one im in heavily on. ill see what sets up towards end of day and post another list.

0 · Reply

BioTuesdays Sep. 8 at 3:23 PM

$KTTA announced that the Safety Review Committee (SRC) has recommended its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004 in adult participants with neurofibromatosis type 1 (NF1) should proceed to Cohort 2, 8mg tablet, without modification. https://biotuesdays.com/2025/09/08/pasithea-enrolls-cohort-2-for-trial-of-pas-004-in-nf1-after-src-review/

0 · Reply

NVDAMillionaire Sep. 8 at 7:40 AM

$KTTA Excellent article that nails exactly where KTTA stands right now. So if you want to update your KTTA knowledge or get acquainted with KTTA, this is a must read. https://beyondspx.com/quote/KTTA/analysis/pasithea-therapeutics-unlocking-macrocyclic-mek-potential-amidst-funding-imperatives-nasdaq-ktta

0 · Reply

ibaian Sep. 7 at 5:37 PM

$KTTA Pasithea Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference, discussing ongoing clinical trials for PAS-004 in advanced cancer patients and NF1-associated plexiform neurofibromas.

0 · Reply

ibaian Sep. 7 at 5:35 PM

$KTTA Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York City, to Monday, September 8, at 5:00 PM Eastern Time.

0 · Reply

TraderJay85 Sep. 7 at 4:58 PM

$NXTT $GYRO $KTTA $SWIN $RAYA This is what im liking for monday. all look good for the gettin. See everyone 1am PT

1 · Reply

Napoliblue Sep. 5 at 1:35 AM

$KTTA another reverse stock split coming ? And never ends with Thiago he gets to live a fat life in South Beach, while people lose their ass on this stock . Even the pump into HC Wainright event has no legs it is what is hope for news and get out of jail

0 · Reply

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Jul 31, 2025, 7:01 AM EDT - 6 weeks ago

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Jun 11, 2025, 7:02 AM EDT - 3 months ago

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Jun 2, 2025, 8:02 AM EDT - 3 months ago

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

May 20, 2025, 7:01 AM EDT - 4 months ago

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

May 14, 2025, 7:02 AM EDT - 4 months ago

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

May 7, 2025, 5:00 PM EDT - 4 months ago

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

May 6, 2025, 11:10 AM EDT - 4 months ago

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

May 6, 2025, 9:29 AM EDT - 4 months ago

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

May 6, 2025, 7:03 AM EDT - 4 months ago

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Apr 29, 2025, 7:02 AM EDT - 4 months ago

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Apr 24, 2025, 7:02 AM EDT - 5 months ago

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Apr 10, 2025, 7:02 AM EDT - 5 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Feb 5, 2025, 6:59 AM EST - 7 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Jan 14, 2025, 8:02 AM EST - 8 months ago

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Sep 26, 2024, 6:44 PM EDT - 1 year ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 26, 2024, 8:56 AM EDT - 1 year ago

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Sep 26, 2024, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Sep 9, 2024, 8:01 AM EDT - 1 year ago

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Sep 3, 2024, 8:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Aug 28, 2024, 9:11 AM EDT - 1 year ago

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

May 28, 2024, 6:59 AM EDT - 1 year ago

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Apr 29, 2024, 7:59 AM EDT - 1 year ago

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 7:59 AM EDT - 1 year ago

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Feb 13, 2024, 7:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Jan 8, 2024, 7:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Jan 2, 2024, 8:35 AM EST - 1 year ago

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Dec 28, 2023, 5:00 PM EST - 1 year ago

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Dec 19, 2023, 5:19 PM EST - 1 year ago

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Dec 11, 2023, 8:01 AM EST - 1 year ago

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Nov 29, 2023, 4:27 PM EST - 1 year ago

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Nov 29, 2023, 7:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Nov 9, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Sep 7, 2023, 4:14 PM EDT - 2 years ago

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Aug 1, 2023, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Jul 20, 2023, 8:43 AM EDT - 2 years ago

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Jul 20, 2023, 8:40 AM EDT - 2 years ago

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Jun 30, 2023, 9:28 AM EDT - 2 years ago

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Jun 6, 2023, 4:30 PM EDT - 2 years ago

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Jun 1, 2023, 7:57 AM EDT - 2 years ago

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

May 3, 2023, 8:26 AM EDT - 2 years ago

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

Feb 23, 2023, 8:00 AM EST - 2 years ago

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P.

Feb 16, 2023, 7:30 AM EST - 2 years ago

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

Jan 18, 2023, 8:00 AM EST - 2 years ago

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

Dec 14, 2022, 5:18 PM EST - 2 years ago

Majority of Stockholders Support Pasithea Directors at Special Meeting

Dec 12, 2022, 7:00 AM EST - 2 years ago

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

Dec 7, 2022, 4:00 PM EST - 3 years ago

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Dec 6, 2022, 8:00 AM EST - 3 years ago

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

Nov 28, 2022, 7:05 PM EST - 3 years ago

Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time

Napoliblue Sep. 13 at 4:22 AM

0 · Reply

Amcollins711 Sep. 11 at 3:57 PM

$MRKR $KTTA my next two

0 · Reply

dustbunnies Sep. 9 at 8:15 AM

$KTTA have the phase 1 results been announced?

0 · Reply

TraderJay85 Sep. 8 at 4:08 PM

0 · Reply

BioTuesdays Sep. 8 at 3:23 PM

0 · Reply

NVDAMillionaire Sep. 8 at 7:40 AM

0 · Reply

ibaian Sep. 7 at 5:37 PM

0 · Reply

ibaian Sep. 7 at 5:35 PM

0 · Reply

TraderJay85 Sep. 7 at 4:58 PM

$NXTT $GYRO $KTTA $SWIN $RAYA This is what im liking for monday. all look good for the gettin. See everyone 1am PT

1 · Reply

Napoliblue Sep. 5 at 1:35 AM

0 · Reply

Sw1ngb0t Sep. 4 at 8:57 PM

$KTTA pop to $1 tomorrow I'd say

0 · Reply

JOHNNY_DANGER Sep. 4 at 5:10 PM

$KTTA Must be ready to rocket....They removed my post about running to 5.00 plus.

1 · Reply

Invest2Create Sep. 3 at 6:37 PM

Unfortunately, this is looking like Top Out Wednesday. In addition to $KTTA topping out, $AMIX has now fallen below its hourly 20 SMA support, and even below its close yesterday. I’m giving AMIX one more chance to rebound and recross that hourly 20 SMA, otherwise I intend to sell before the close.

1 · Reply

JOHNNY_DANGER Sep. 3 at 2:18 PM

$KTTA This could easily squeeze to 3.00 plus.

0 · Reply

Sw1ngb0t Sep. 3 at 2:08 PM

$KTTA nice pullback. now it's a nice 20% play

0 · Reply

Invest2Create Sep. 3 at 1:56 PM

I’ve sold $KTTA as it looks to be topping out and heading down. $KTTA does have a history in recent months of gapping up 100% or so for a day from lows. But it has to reach and establish those lows first. I will be watching for those, but for now, I’m out and

0 · Reply

SamuraiX7 Sep. 3 at 1:21 PM

$BCTX $ENTO $HOTH $KTTA HOTH released a great news , not selling any of my shares 😊

1 · Reply

ArbysRawMeats Sep. 3 at 12:24 PM

$KTTA early technicals say she’s gearing up for strength, hopefully this is the run

0 · Reply

Tom678 Sep. 3 at 11:46 AM

$BCTX $ENTO $HOTH $KTTA HOTH is about to get HoT 🔥

0 · Reply

S2K_TradeZ Sep. 3 at 9:01 AM

🦉Bio Momentum Names Worth Watching today: $KTTA, $BCTX, $HOTH, $ENTO

1 · Reply

NextRunnerTV Sep. 3 at 1:43 AM

Tune into my TikTok 👉 @nextrunnertv the amount of winning calls I’ve made is unreal! 🚀🔥 Don’t miss the next big runner. https://www.tiktok.com/@NextRunnerTV $UMAC $NVTS $KTTA $VEEE

0 · Reply

ArbysRawMeats Sep. 3 at 1:40 AM

$KTTA volume has been multiples higher for the last many sessions

0 · Reply

Market Cap	5.74M
Revenue (ttm)	0.00
Net Income (ttm)	-13.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	52,800
Avg Vol	136,956
Day's Range	N/A - N/A
Shares Out	7.44M
Stochastic %K	18%
Beta	0.28
Analysts	Strong Buy
Price Target	$2.00